Skip to main content

Advertisement

SpringerLink
Log in

Is high-dose radioimmunotherapy needed in non-Hodgkin’s lymphoma?

  • Controversies
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Goldenberg DM. Radioimmunotherapy. In: Freeman LM, ed. Nuclear medicine annual 2001. Philadelphia: Lippincott Williams and Wilkins; 2001:167–206.

    Google Scholar 

  2. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43:693–713.

    CAS  PubMed  Google Scholar 

  3. Postema EJ, Boerman OC, Oyen WJ, Raemaekers JM, Corstens FH. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma. Eur J Nucl Med 2001; 28:1725–1735.

    Article  CAS  PubMed  Google Scholar 

  4. Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 1999; 5:3304–3314.

    Google Scholar 

  5. DeNardo SJ, Kroger LA, MacKenzie MR, Mirick GR, Shen S, DeNardo GL. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody. Cancer Biother Radiopharm 1998; 13:1–12.

    Article  CAS  PubMed  Google Scholar 

  6. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med 1997; 38:409–418.

    CAS  PubMed  Google Scholar 

  7. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219–1224.

    Article  CAS  PubMed  Google Scholar 

  8. Marshall NA, DeVita VT Jr. Hodgkin’s disease and transplantation: a room with a (nontransplanter’s) view. Semin Oncol 1999; 26:67–73.

    CAS  PubMed  Google Scholar 

  9. Montemurro F, Ueno NT, Rondon G, Aglietta M, Champlin RE. High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin Breast Cancer 2000; 1:197–209.

    Article  CAS  PubMed  Google Scholar 

  10. Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997; 44:179–188.

    Article  CAS  PubMed  Google Scholar 

  11. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin’s lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995; 55:5899–5907.

    Google Scholar 

  12. Tsai DE, Schuster SJ, Matthies A, Moore HC, Alavi A, Juweid ME, Goldenberg DM, Stadtmauer EA. Progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. Clin Lymphoma 2000; 1:62–66.

    Article  CAS  PubMed  Google Scholar 

  13. Rose LM, Deng CT, Scott SL, Xiong CY, Lamborn KR, Gumerlock PH, DeNardo GL, Meares CF. Critical Lym-1 binding residues on polymorphic HLA-DR molecules. Mol Immunol 1999; 36:789–797.

    Article  CAS  PubMed  Google Scholar 

  14. DeNardo GL, DeNardo SJ, O’Donnell RT, Kroger LA, Kukis DL, Meares CF, Goldstein DS, Shen S. Are radiometallabeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin’s lymphoma. Clin Lymphoma 2000; 1:118–126.

    Article  CAS  PubMed  Google Scholar 

  15. Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, Raubitschek A, Karvelis K, Schultheiss T, Witzig TE, Belanger R, Spies S, Silverman DHS, Berlfein JR, Ding E, Grillo-López AJ. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma. Eur J Nucl Med 2000; 27:766–777.

    Article  CAS  PubMed  Google Scholar 

  16. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336–4342.

    Article  CAS  PubMed  Google Scholar 

  17. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA. Randomized controlled trial of yttrium-90-labeled Ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:2453–2463.

    Article  CAS  PubMed  Google Scholar 

  18. Witzig TE, White CA, Flinn IW, et al. Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin’s lymphoma (NHL). Blood 2000; 96:507a (abstract 2183).

    Google Scholar 

  19. Witzig TE, Gordon LI, Wiseman GA, et al. Zevalin radioimmunotherapy is safe and well tolerated in patients with relapsed or refractory, B cell non-Hodgkin’s lymphoma (NHL). Blood 2000; 96: 731a (abstract 3160).

    Google Scholar 

  20. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96:1259–1266.

    CAS  PubMed  Google Scholar 

  21. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329:459–465.

    Article  CAS  PubMed  Google Scholar 

  22. Kaminski M, Zelenetz AD, Press OW, et al. Multicenter, phase III study of iodine-131 tositumomab (anti-B1 antibody) for chemotherapy-refractory low-grade or transformed low-grade non-Hodgkin’s lymphoma. Blood 1998; 92:1296a (abstract).

    Google Scholar 

  23. Wahl RL, Zasadny KR, Estes J, et al. Single center experience with iodine I-131 tositumomab radioimmunotherapy for previously untreated follicular lymphoma (FL). J Nucl Med 2000; 41: 79 (abstract 309).

    Google Scholar 

  24. Leonard JP, Coleman M, Kostakoglu L, et al. Fludarabine monophosphate followed by I-131 tositumomab for untreated low-grade and follicular non-Hodgkin’s lymphoma (NHL). Blood 1999; 94 [Suppl 1]: 90a (abstract 393).

    Google Scholar 

  25. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131IB1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346:336–340.

    Article  CAS  PubMed  Google Scholar 

  26. Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16:3270–3278.

    CAS  PubMed  Google Scholar 

  27. Johnson TA, Press OW. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol 2000; 79:175–182.

    Article  CAS  PubMed  Google Scholar 

  28. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934–2942.

    CAS  PubMed  Google Scholar 

  29. Behr TM, Kaufmann CC, Wörmann B, Riggert J, Gratz S, Béhé M, Griesinger F, Brittinger G, Becker W. High-dose, myeloablative radioimmunotherapy of non-Hodgkin’s lymphoma with the 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support.

  30. Barista I, Romaguera JE, Cabanillas F. Mantle-cell lymphoma. Lancet Oncol 2001; 2:141–148.

    Article  CAS  PubMed  Google Scholar 

  31. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17:3793–3803.

    CAS  PubMed  Google Scholar 

  32. Behr TM, Griesinger F, Riggert J, Gratz S, Béhé M, Kaufmann CC, Wörmann B, Brittinger G, Becker W. Highdose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study. Cancer 2002; 94:1363–1372.

    Article  CAS  PubMed  Google Scholar 

  33. Gopal AK, Rajendran JG, Petersdorf SH, Maloney DG, Eary JF, Wood BL, Gooley TA, Bush SA, Durack LD, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99:3158–3162.

    Article  CAS  PubMed  Google Scholar 

  34. Goldenberg DM, ed. Cancer therapy with radiolabeled antibodies. Boca Raton, Fl.: CRC Press, 1995.

    Google Scholar 

  35. Illidge TM, Brock S. Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. Curr Pharm Des 2000; 6:1399–1418.

    Article  CAS  PubMed  Google Scholar 

  36. DeNardo SJ, Kroger LA, DeNardo GL. A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 1999; 11:563–569.

    Article  CAS  PubMed  Google Scholar 

  37. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999; 26:58–65.

    CAS  PubMed  Google Scholar 

  38. Vose JM. Antibody-targeted therapy for low-grade lymphoma. Semin Hematol 1999; 36:15–20.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine of the Philipps-University of Marburg, Baldingerstraße, 35043, Marburg, Germany

    Thomas M. Behr

Authors
  1. Thomas M. Behr
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Behr, T.M. Is high-dose radioimmunotherapy needed in non-Hodgkin’s lymphoma?. Eur J Nucl Med 29, 1248–1254 (2002). https://doi.org/10.1007/s00259-002-0928-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-002-0928-9

Keywords

Search

Navigation